Jeffrey Rudolph ’78 developed a master plan to build the California Science Center into a center of science, learning, and ...

Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full ...